Search Results for

MK7339-003

Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

Continue Reading »

---

A221805

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Continue Reading »

---

GI005 (Suspended)

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery (Suspended)

Continue Reading »

---

S1820

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Continue Reading »

---

A021703

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS)

Continue Reading »

---

WF-1806

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Continue Reading »

---

ES2018-01 (Suspended)

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors (Suspended)

Continue Reading »

---

GI004

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Continue Reading »

---

A021502

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Adjuvant  (1)    Metastatic  (2)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (5)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (5)    Breast Cancer Neoadjuvant  (1)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (21) Carcinoid Tumors  (2) Colorectal Cancer  (9)    Metastatic  (4) Esophageal Cancer  (2) Gastric Cancer  (2)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (4)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (5)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (18)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (4)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (3)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (6)       Extensive Stage SCLC  (3) Lymphoma  (8)    Non-Hodgkin’s Lymphoma  (4)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (3)          Relapsed/Refractory  (3) MATCH Trial  (1) MDS  (3) Melanoma  (7)    Metastatic  (3) Merkel Cell Carcinoma  (1) Multiple Myeloma  (1) Pancreatic  (6)    Metastatic Disease  (4) Prostate  (8) Renal Cell/Kidney Cancer  (6)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)